caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets EU OK for Ablynx flagship drug Cablivi

The EU regulator has cleared Cablivi (caplacizumab) for adults with aTTP, and Sanofi says that the drug is the first in Europe to be approved specifically for the rare blood-clotting

Latest news

Dupixent bounce-back helps stem diabetes declines at Sanofi

hoping that the 3.9bn takeover of antibody specialist Ablynx and lead rare disease drug caplacizumab will also pay off in the years to come.
Sanofi’s rare blood disorder drug Cablivi set for European approval

The EMA’s Committee for Medicinal Products for Human Use (CHMP) gave its blessing to Cablivi (caplacizumab) at its monthly meeting last week, along with three other rare disease therapies, two
Sanofi poaches Peugeot's finance head

It also made a play for nanobody focused biopharma Ablynx, which it acquired for 3.9bn, along with its lead candidate and orphan drug caplacizumab for rare blood disorder acquired thrombotic
Sanofi appoints ex-Roche Reed as new R&D head

Sanofi currently has just one drug pending FDA approval - Ablynx’s caplacizumab, a new treatment for blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP), but needs more filings over the next
Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

With operating conditions increasingly tough for its core diabetes franchise as well, Novo has been trying to grow its pipeline, but an attempt to buy Ablynx and its lead product caplacizumab

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Strategically caplacizumab represented a good fit for Novo Nordisk as it complements the company's portfolio of products focused on haemophilia. ... Acquisition company. 7, 000. Ablynx/Sanofi. Nanobody platform product pipeline; lead product caplacizumab

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Novo Nordisk target Ablynx reshuffles its board

lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Manager- 4 days per week or full-time: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director or Senior Account Director: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Account Manager – Healthcare Advertising: Salary TBC

Graduate Scientific Editor: DOE

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Sudler London - Account Director: Competitive

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Sudler London - Senior Medical Writer: Competitive

Associate Scientific Director: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Healthcare PR Senior Account Manager: Salary TBC

Senior Medical Writer, MedComms Agency: Salary TBC

Account Manager: Negotiable

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Market Access Consultant - Greater Manchester: Negotiable

Medical Writers Required - Hertfordshire: Competitive

Systematic Review Lead- London: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....